Add to ORKGBET bromodomain inhibition targets both c-MYC and IL7R in high-risk acute lymphoblastic leukemi
Purpose: Approximately 50% of patients with diffuse large B-cell lymphoma (DLBCL) enter long-term re...
In the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL), NF-B activity i...
Bromodomain and extra terminal protein (BET) inhibitors are first-in-class targeted therapies that d...
MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to modulate the f...
Bromodomains (BRDs) have emerged as compelling targets for cancer therapy. The development of select...
Summary: BET inhibitors (BETi) target bromodomain-containing proteins and are currently being evalua...
Summary The bromodomain and extraterminal (BET) protein BRD4 is a validated drug target in leukemia,...
Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly for hemato...
Bromodomains (BRDs) have emerged as compelling targets for cancer therapy. The development of select...
Paediatric B-precursor ALL is a highly curable disease, however, treatment resistance in some patien...
Bromodomain and extra terminal (BET) proteins comprise the ubiquitously expressed BRD2, BRD3, BRD4 a...
Acute lymphoblastic leukemia (ALL) remains the leading cause of cancer-related death in children and...
Lysine acetylation is a key mechanism that regulates chromatin structure; aberrant acetylation level...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
Abstract Background Targeted therapy has always been the focus in developing therapeutic approaches ...
Purpose: Approximately 50% of patients with diffuse large B-cell lymphoma (DLBCL) enter long-term re...
In the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL), NF-B activity i...
Bromodomain and extra terminal protein (BET) inhibitors are first-in-class targeted therapies that d...
MYC contributes to the pathogenesis of a majority of human cancers, yet strategies to modulate the f...
Bromodomains (BRDs) have emerged as compelling targets for cancer therapy. The development of select...
Summary: BET inhibitors (BETi) target bromodomain-containing proteins and are currently being evalua...
Summary The bromodomain and extraterminal (BET) protein BRD4 is a validated drug target in leukemia,...
Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly for hemato...
Bromodomains (BRDs) have emerged as compelling targets for cancer therapy. The development of select...
Paediatric B-precursor ALL is a highly curable disease, however, treatment resistance in some patien...
Bromodomain and extra terminal (BET) proteins comprise the ubiquitously expressed BRD2, BRD3, BRD4 a...
Acute lymphoblastic leukemia (ALL) remains the leading cause of cancer-related death in children and...
Lysine acetylation is a key mechanism that regulates chromatin structure; aberrant acetylation level...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
Abstract Background Targeted therapy has always been the focus in developing therapeutic approaches ...
Purpose: Approximately 50% of patients with diffuse large B-cell lymphoma (DLBCL) enter long-term re...
In the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL), NF-B activity i...
Bromodomain and extra terminal protein (BET) inhibitors are first-in-class targeted therapies that d...